Viridian Therapeutics, Inc./DE Cash and Cash Equivalents
Viridian Therapeutics, Inc./DE (VRDN) had Cash and Cash Equivalents of $24.86 million as of 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2019-11-08
- 2019-09-30: Cash and Cash Equivalents, at Carrying Value $24.86M.
- 2019-06-30: Cash and Cash Equivalents, at Carrying Value $24.01M.
- 2019-03-31: Cash and Cash Equivalents, at Carrying Value $18.20M.
- 2018-12-31: Cash and Cash Equivalents, at Carrying Value $32.61M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2019-09-30 | $24.86M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $24.01M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $18.20M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $32.61M 10-Q · filed 2019-11-08 | |
| 2018-09-30 | $31.70M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $43.40M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $78.10M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $47.44M 10-Q · filed 2019-11-08 | |
| 2017-09-30 | $42.80M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $46.34M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $46.34M 10-Q · filed 2018-08-08 | $54.27M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $22.10M 10-K · filed 2019-03-14 | $3.34M 10-K · filed 2017-03-24 |
| 2016-09-30 | $24.60M 10-Q · filed 2017-11-09 | $5.35M 10-Q · filed 2016-10-26 |
| 2016-06-30 | $8.38M 10-Q · filed 2017-08-11 | $6.50M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $16.96M 10-Q · filed 2017-05-11 | $8.56M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $21.23M 10-K · filed 2018-03-15 | $10.83M 10-K · filed 2016-03-21 |
| 2015-09-30 | $12.12M 10-Q · filed 2016-10-26 | |
| 2015-06-30 | $10.45M 10-Q · filed 2016-08-15 | |
| 2015-03-31 | $13.27M 10-Q · filed 2016-05-16 | |
| 2014-12-31 | $5.12M 10-K · filed 2017-03-24 | |
| 2014-09-30 | $6.39M 10-Q · filed 2015-11-13 | $6.39M 10-Q · filed 2014-11-14 |
| 2014-06-30 | $7.70M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $209.00K 10-K · filed 2016-03-21 | $209.35K 10-Q · filed 2014-08-14 |
| 2013-09-30 | $226.25K 10-Q · filed 2014-11-14 | |
| 2013-06-30 | $247.06K 10-Q · filed 2014-08-14 | |
| 2012-12-31 | $112.53K 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |